Replies to post #8137 on Ariad Pharmaceuticals Inc fka ARIA

[BTH]

Thanks.

Reading these myself.

IMO, this data is pretty much what we already know, with the exception of the "trending" of OS. It's going to take the real presentation to get to the gut of all of these.

Nothing big here.

[BTH]

[quoteThe rapid progression of metastatic sarcomas demonstrates the aggressive nature of these malignancies, and maintenance therapy with R will provide a new option for pts with this life-threatening disease. ][/quote]

Thats the key takeaway here. Despite insufficient OS data, its clear that Merck intends to go to market with this drug. I assume OS will be closer to Dews figure when they report final data. Right now, its almost two and one half months, which isnt bad.

To be honest, I kinda wish Ridaforolimus would just go away..from a shareholders perspective. Underwhelming, at best.